liver and GI disease in pregnancy

in review 5 min read Updated 2026-10-28
liver and GI disease in pregnancy

AST/ALT, bilirubin, GGT don’t change in pregnancy — any rise is pathological (ALP ↑ is placental). Diagnose by trimester + pattern: HG (T1), ICP (pruritus, bile acids >19 µmol/L), HELLP (≥20 wk, haemolysis + plt <100, usually hypertensive), AFLP (late T3, hypoglycaemia + coagulopathy + AKI). HELLP and AFLP → stabilise and deliver.

pattern recognition

hyperemesisICPHELLPAFLP
timingT1 (resolves ~20 wk)late T2–T3≥20 wk, ~30% postpartumlate T3, occasionally postpartum
clinicalvomiting, >5% weight loss, dehydrationpruritus palms/soles, worse at night, no rashRUQ/epigastric pain, nausea, ± HTN/proteinuriaN/V, abdominal pain, polyuria/polydipsia, jaundice, encephalopathy
AST/ALTmild (<200)100s100s–1000smoderate (often <500–1000)
bilirubinnormal/mildnormal/mild↑ unconjugated (haemolysis)↑↑ conjugated
discriminatorsketonuria, ↓K⁺bile acids >19 µmol/LLDH ↑, haptoglobin ↓, schistocytes, plt <100glucose ↓, INR ↑, fibrinogen ↓, Cr ↑, NH₃ ↑, WBC ↑
treatmentantiemetics, fluids, thiamineUDCA, timed deliveryBP, MgSO₄, delivercorrect glucose/coagulopathy, deliver
  • Always exclude non-obstetric causes: viral hepatitis (A, B, C, E — fulminant in pregnancy), HSV hepatitis (anicteric, very high ALT, fever), gallstones/cholangitis, DILI, Budd–Chiari, AIH — see approach to elevated liver enzymes
  • Workup: CBC + film, AST/ALT, ALP, GGT, bilirubin, INR, fibrinogen, glucose, LDH, haptoglobin, Cr, uPCR, non-fasting bile acids, viral serology, RUQ US

HELLP

  • Complication of preeclampsia; 10–20% normotensive, 15% without proteinuria
  • Tertiary centre; treat severe BP + magnesium sulfate; deliver (>34 wk or deteriorating → now; <34 wk stable → steroids then deliver)
  • Platelets (SOGC): transfuse if <20 before vaginal, <50 before caesarean, or with active bleeding, rapid fall, or coagulopathy; recheck often — counts fall fast
  • Corticosteroids to treat HELLP: not recommended (lab improvement only)
  • Hepatic haematoma/rupture: severe RUQ/shoulder pain, hypotension, Hb drop → CT/US, IR/surgery
  • Labs often worsen for 24–48 h postpartum, then recover within ~3–5 d
  • Not improving by ~day 3, or Cr/schistocytes/thrombocytopenia disproportionate → TTP or complement-mediated HUS — see haematology in pregnancy

acute fatty liver of pregnancy

  • Mitochondrial β-oxidation defect — foetal LCHAD deficiency in a subset → screen the neonate
  • Swansea criteria (≥6 of 14, no other cause): vomiting, abdominal pain, polydipsia/polyuria, encephalopathy, ↑bilirubin, hypoglycaemia, ↑urate, leukocytosis, ascites/bright liver on US, ↑AST/ALT, ↑NH₃, AKI, coagulopathy, microvesicular steatosis on biopsy
  • Biopsy almost never needed — don’t delay delivery for it
  • Management: ICU, dextrose infusion (q1h glucose), FFP/cryoprecipitate for coagulopathy, prompt delivery after stabilisation; hepatology ± transplant centre if failure persists after delivery
  • Recovery usually begins 2–3 d after delivery
AFLP vs HELLP

Hypoglycaemia, INR >1.5, low fibrinogen, encephalopathy, and conjugated hyperbilirubinaemia point to AFLP (synthetic failure). HELLP is haemolysis + thrombocytopenia with relatively preserved synthetic function until DIC. Overlap is common — both mean delivery.


intrahepatic cholestasis of pregnancy (SOGC 2024)

  • Diagnosis: pruritus (palms/soles) + non-fasting bile acids >19 µmol/L; exclude other liver disease
  • Repeat bile acids + LFTs every 2–4 wk (management uses the peak level); repeat if typical symptoms + initial normal result
  • UDCA 10–15 mg/kg/d in 2–3 divided doses (max 20 mg/kg/d) → modest ↓ pruritus, ↓ ALT; no ↓ composite of perinatal death, preterm birth, NICU admission (PITCHES (2019))
  • Adjuncts: emollients, antihistamines; rifampicin 300–1200 mg/d for refractory cases. Dexamethasone, cholestyramine, SAMe are ineffective
  • ↑ preeclampsia, GDM, preterm birth, NICU admission; stillbirth risk rises sharply at bile acids ≥100 µmol/L
peak bile acids (µmol/L)suggested delivery (SOGC)
20–3939⁺⁰–39⁺⁶ wk
40–6938⁺⁰–38⁺⁶ wk
70–9936⁺⁰–37⁺⁶ wk
≥100by 36 wk (earlier if comorbidity, prior ICP stillbirth)
  • Postpartum: resolves within 1–2 (up to 4) wk; confirm at 6 wk, persistent → investigate (PBC, PSC, ABCB4)
  • Recurrence 70–90%; progestin-only contraception preferred; later ↑ gallstones, hepatobiliary disease
intrahepatic cholestasis of pregnancy

Foetal-risk condition. Bile acids 65 µmol/L at 32 wk → UDCA, repeat bile acids q2–4 wk, plan delivery 38 wk.


nausea, vomiting, hyperemesis (SOGC 2016)

  • NVP in 50–80%; HG 0.3–2% (vomiting, >5% weight loss, ketonuria, electrolyte derangement)
  • Stepwise: stop iron-containing prenatals (folic acid only), small frequent meals, ginger → doxylamine–pyridoxine → dimenhydrinate/H1 antihistamine → metoclopramide or prochlorperazine/chlorpromazine → ondansetron (check QTc)
  • HG admission: IV fluids (dextrose-containing after thiamine), K⁺/Mg²⁺/phosphate, thiamine before dextrose (Wernicke’s), IV antiemetics, PPI/H2RA; refractory → corticosteroids (after 10 wk) with obstetric input
  • New N/V after 20 wk ≠ NVP → think HELLP, AFLP, pyelonephritis, appendicitis
  • GERD common: calcium carbonate → H2RA → PPI (all acceptable)
  • Cannabis hyperemesis — ask; counsel cessation

viral hepatitis in pregnancy

  • HBV (SOGC): universal HBsAg screening; tenofovir (TDF) from 28–32 wk if HBV DNA >200,000 IU/mL; infant HBIG + vaccine within 12 h; breastfeeding fine, including on TDF — see viral hepatitis
    • CASL 2025 starts earlier: TDF or TAF as soon as possible and no later than the second trimester; screen HBsAg every first trimester; continue up to 12 weeks postpartum (longer if family planning continues), then ALT every 4 weeks × 3 months and at 6 months; infant HBIG + vaccine as soon as possible after birth, doses 2–3 by 6 months, test at 1–4 months after the last dose; breastfeeding on TDF/TAF allowed
  • HCV: universal anti-HCV screening each pregnancy (SOGC); no DAA in pregnancy/breastfeeding — treat postpartum; avoid scalp electrodes/foetal blood sampling; no CS indication; breastfeed unless nipples cracked/bleeding; test infant (RNA at ≥2 months)
  • HEV: high maternal mortality in T3 — consider in travellers from endemic areas

evidence

  • PITCHES (2019) — n=605; UDCA didn’t reduce composite perinatal outcome (stillbirth, preterm birth, NICU); modest itch improvement
  • Ovadia, Lancet. 2019 — IPD meta-analysis; stillbirth risk not ↑ until bile acids ≥100 µmol/L (HR ~30)

Prepared 2026-10-28. Not yet verified — check every number against the sources.

Key references

+2 more sources

Suggest a correction liver and GI disease in pregnancy